GR3032660T3 - Lymphokine gene therapy of cancer. - Google Patents

Lymphokine gene therapy of cancer.

Info

Publication number
GR3032660T3
GR3032660T3 GR20000400358T GR20000400358T GR3032660T3 GR 3032660 T3 GR3032660 T3 GR 3032660T3 GR 20000400358 T GR20000400358 T GR 20000400358T GR 20000400358 T GR20000400358 T GR 20000400358T GR 3032660 T3 GR3032660 T3 GR 3032660T3
Authority
GR
Greece
Prior art keywords
tumor
site
patient
cytokine gene
cancer
Prior art date
Application number
GR20000400358T
Other languages
English (en)
Inventor
Robert E Sobol
H Gage Fred
Ivor Royston
Theodore Friedman
Habib Fakhrai
Original Assignee
San Diego Regional Cancer Cent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27119842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3032660(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by San Diego Regional Cancer Cent filed Critical San Diego Regional Cancer Cent
Publication of GR3032660T3 publication Critical patent/GR3032660T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR20000400358T 1991-10-25 2000-02-14 Lymphokine gene therapy of cancer. GR3032660T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78135691A 1991-10-25 1991-10-25
US86364192A 1992-04-03 1992-04-03
PCT/US1992/008999 WO1993007906A1 (en) 1991-10-25 1992-10-23 Lymphokine gene therapy of cancer

Publications (1)

Publication Number Publication Date
GR3032660T3 true GR3032660T3 (en) 2000-06-30

Family

ID=27119842

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000400358T GR3032660T3 (en) 1991-10-25 2000-02-14 Lymphokine gene therapy of cancer.

Country Status (9)

Country Link
EP (1) EP0668781B1 (el)
JP (1) JP3524918B2 (el)
AT (1) ATE188125T1 (el)
CA (1) CA2121127A1 (el)
DE (1) DE69230506T2 (el)
DK (1) DK0668781T3 (el)
ES (1) ES2144426T3 (el)
GR (1) GR3032660T3 (el)
WO (1) WO1993007906A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US6241982B1 (en) 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
CA2158936C (en) 1993-11-18 2012-02-21 Jack R. Barber Compositions and methods for utilizing conditionally lethal genes
FR2713657B1 (fr) * 1993-12-13 1996-03-01 Transgene Sa Nouveaux vecteurs pour le traitement du sida.
EP0734440A1 (en) * 1993-12-14 1996-10-02 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions
DE4406073A1 (de) * 1994-02-24 1995-08-31 Univ Ludwigs Albert Verfahren zur Herstellung von humanen, klonogenen Fibroblasten, Verfahren zur Gentransfizierung von Fibroblasten und so erhaltene Fibroblasten
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
JP3822261B2 (ja) * 1994-09-09 2006-09-13 財団法人癌研究会 癌の遺伝子治療剤
WO1996013275A1 (en) * 1994-10-31 1996-05-09 Tkb Associates Limited Partnership Methods and products for enhancing immune responses
PT817858E (pt) * 1995-03-09 2003-09-30 Gsf Forschungszentrum Umwelt U Preparacoes fotoprotectoras que compreendem derivados de triazina
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
EP0834323A1 (en) * 1996-09-30 1998-04-08 Introgene B.V. Cytokine gene therapy for treatment of malignacies
US6187307B1 (en) 1997-01-31 2001-02-13 Research Corporation Technologies, Inc. Cancer immunotherapy with semi-allogeneic cells
US6464973B1 (en) * 1998-02-02 2002-10-15 Johns Hopkins University, School Of Medicine Universal GM-CSF expressing bystander human K562 cell line
US6342216B1 (en) * 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
AU2001253031A1 (en) * 2000-03-31 2001-10-15 Novarx Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor
US7101543B2 (en) 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
EP1285059A2 (en) 2000-05-31 2003-02-26 The Board Of Regents, The University Of Texas System Adjuvant preparation for the induction of specific immunity
CN1929867A (zh) * 2004-01-13 2007-03-14 株式会社载体研究所 肿瘤的基因治疗，即利用编码免疫刺激性细胞因子的单链负链rna病毒载体进行的治疗
WO2006105255A2 (en) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
US20220401541A1 (en) * 2019-11-02 2022-12-22 Figene, Llc Intratumoral administration of immune cellular therapeutics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0551401T3 (da) * 1990-09-14 1996-01-22 Univ Texas Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet

Also Published As

Publication number Publication date
CA2121127A1 (en) 1993-04-29
JP3524918B2 (ja) 2004-05-10
EP0668781A4 (en) 1995-06-14
DK0668781T3 (da) 2000-04-17
DE69230506D1 (de) 2000-02-03
ES2144426T3 (es) 2000-06-16
JPH07503455A (ja) 1995-04-13
EP0668781A1 (en) 1995-08-30
DE69230506T2 (de) 2000-06-21
WO1993007906A1 (en) 1993-04-29
EP0668781B1 (en) 1999-12-29
ATE188125T1 (de) 2000-01-15

Similar Documents

Publication Publication Date Title
GR3032660T3 (en) Lymphokine gene therapy of cancer.
CA2267157A1 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
ATE323774T1 (de) Antitumor-gentherapie bei immuno-und/oder entzündungsmodulation
SG46445A1 (en) Vaccines against cancer and infectious diseases
GR3035627T3 (en) A mammalian cytokine, il-11.
IL98957A (en) Antigen-specific cytotoxic lymphocytes obtained by culture with IL-7 without stimulation by an antigen or mitogen
IL87621A0 (en) Conjugates of cytokines with immunoglobulins,their preparation and pharmaceutical compositions containing them
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
EP0202642A3 (en) Process for the in vitro immunization of human splenocytes against tumor associated antigens
IL92009A0 (en) Cell lines,monoclonal anti-bodies and pharmaceutical compositions containing the same
Tanigawa et al. Gene gun application in the generation of effector T cells for adoptive immunotherapy
Yancey et al. Interferon: Status in treatment of skin disease
Stoeck et al. In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells
Yu et al. The humoral antitumor responses induced by IL-4 gene-modified tumor vaccine
Suzuki et al. A Pathogenic Role of Th2 Cells and Their
NO920160L (no) Cytokin- og hormonbaerere for konjugatvaksiner
IE861358L (en) Process for the in vitro immunization of human splenocytes¹against tumor associated antigens

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees